Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma

Blood

Volumn 108, Issue 12, 2006, Pages 3871-3880

  Lambert, Marion ^b   Gannagé, Monique ^b   Karras, Alexandre ^b   Abel, Michal ^b   Legendre, Christophe ^b   Kerob, Delphine ^b   Agbalika, Felix ^b   Girard, Pierre Marie ^b   Lebbe, Celeste ^b   Caillat Zucman, Sophie ^a  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN B; HLA A ANTIGEN; TETRAMER; VIRUS VACCINE;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; IMMUNE RESPONSE; INFECTION RESISTANCE; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; OPEN READING FRAME; PHENOTYPE; PRIORITY JOURNAL; SKIN BIOPSY; VIRUS LOAD; VIRUS REPLICATION;

EID: 33845239215     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-03-014225     Document Type: Article

References (42)

1. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266:1865-1869.
2. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases, part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis. 2002;2:281-292.
3. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases, part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis. 2002;2:344-352.
4. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study: Swiss HIV Cohort Study. BMJ. 1999;319:23-24.
5. Nagy S, Gyulai R, Kemeny L, Szenohradszky P, Dobozy A. Iatrogenic Kaposi's sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppressive therapy. Transplantation. 2000;69:2230-2231.
6. Zhong W, Wang H, Herndier B, Ganem D. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci U S A. 1996;93:6641-6646.
7. Osman M, Kubo T, Gill J, et al. Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol. 1999;73:6136-6140.
8. + cytotoxic T lymphocyte responses to lytic proteins of human herpes virus 8 in human immunodeficiency virus type 1-infected and -uninfected individuals. J Infect Dis. 2000;182:928-932.
9. + T-cell response to viral lytic cycle proteins. Blood. 2001;97:2366-2373.
10. Brander C, O'Connor P, Suscovich T, et al. Definition of an optimal cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma-associated herpesvirus kaposin protein. J Infect Dis. 2001;184:119-126.
11. Micheletti F, Monini P, Fortini C, et al. Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8. Immunology. 2002;106:395-403.
12. Wilkinson J, Cope A, Gill J, et al. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol. 2002;76:2634-2640.
13. + T-cell epitope for the glycoprotein B homolog of human herpesvirus 8. Blood. 2002;99:3360-3366.
14. Bourboulia D, Aldam D, Lagos D, et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS. 2004;18:485-493.
15. + T cell epitopes within lytic antigens of human herpes virus 8. J Immunol. 2006;176:923-930.
16. Larroche C, Agbalika F, Poirel H, et al. Epstein-Barr virus and human herpesvirus 8 coinfection and concomitant extranodal nasal-type NK/T cell lymphoma and Castleman disease: case report. Clin Infect Dis. 2003;36:e107-e110.
17. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96.
18. + T cell response during acute and persistent murine gamma-herpesvirus infection. Eur J Immunol. 1999;29:1059-1067.
19. Pittet MJ , Valmori D, Dunbar PR, et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med. 1999;190:705-715.
20. Gannagé M, Abel M, Michallet AS, et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol. 2005;174:8210-8218.
21. + T lymphocytes with changes in viral load: the RESTIM and COMET Study Groups. J Immunol. 2000;165:1692-1704.
22. Zhang D, Shankar P, Xu Z, et al. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood. 2003;101:226-235.
23. + T cells. J Immunol. 2004;172:1744-1753.
24. + T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8:379-385.
25. Parravicini C, Olsen SJ, Capra M, et al. Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients. Blood. 1997;90:2826-2829.
26. Lebbe C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS. 1998;12:F45-F49.
27. Kalams SA, Goulder PJ, Shea AK, et al. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol. 1999;73:6721-6728.
28. Woodberry T, Suscovich TJ, Henry LM, et al. Impact of Kaposi sarcoma-associated herpesvirus (KSHV) burden and HIV coinfection on the detection of T cell responses to KSHV ORF73 and ORF65 proteins. J Infect Dis. 2005;192:622-629.
29. Dukers NH, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. AIDS. 2003;17:1717-1730.
30. Brander C, Suscovich T, Lee Y, et al. Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus. J Immunol. 2000;165:2077-2083.
31. Coscoy L, Ganem D. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc Natl Acad Sci U S A. 2000;97:8051-8056.
32. Ishido S, Choi JK, Lee BS, et al. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity. 2000;13:365-374.
33. Coscoy L, Ganem D. A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. J Clin Invest. 2001;107:1599-1606.
34. Ishido S, Wang C, Lee BS, Cohen GB, Jung JU. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol. 2000;74:5300-5309.
35. Tomescu C, Law WK, Kedes DH. Surface down-regulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus. J Virol. 2003;77:9669-9684.
36. Promadej N, Costello C, Wernett MM, et al. Broad human immunodeficiency virus (HIV)-specific T cell responses to conserved HIV proteins in HIV-seronegative women highly exposed to a single HIV-infected partner. J Infect Dis. 2003;187:1053-1063.
37. Kamal SM, Amin A, Madwar M, et al. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol. 2004;78:12252-12258.
38. Rowland-Jones SL, Dong T, Fowke KR, et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest. 1998;102:1758-1765.
39. + T cells restricted by donor HLA alleles following liver transplantation. J Immunol. 2004;173:5355-5359.
40. Barozzi P, Luppi M, Facchetti F, et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med. 2003;9:554-561.
41. BioInformatics and Molecular Analysis Section, Computational Bioscience and Engineering Lab, Division of Computational Bioscience, Center for Information Technology, National Institutes of Health. http://bimas.dcrt.nih. gov. Accessed July 2006.
42. SYFPEITHI: a database of MHC ligands and peptide motifs (ver. 1.0). http://www.syfpeithi.de. Accessed July 2006.